Pre-clinical Study Points to Increased Autonomy and Efficiency in Surgeons’ Workflows
Early testing at IRCAD demonstrates promising effects of automated instrument switching.
A pre-clinical usability study conducted at IRCAD suggests that Symphera’s automated instrument-switching system could enhance surgeon autonomy and streamline workflow steps during minimally invasive procedures.
The study evaluated how reducing manual instrument exchange may decrease workload, improve consistency, and support more controlled procedural flow. These findings will inform ongoing development and preparation for future pre-clinical testing.
Renowned Surgeon Dr. Brett Parker Joins Symphera as Advisor
Dr. Parker brings extensive expertise in minimally invasive and robotic surgery.
Symphera welcomes Dr. Brett Parker, Assistant Professor of Surgery at Johns Hopkins School of Medicine, as a clinical advisor. His experience in foregut and bariatric surgery brings valuable insight as Symphera refines its instrument-switching platform.
Dr. Parker will support clinical strategy, workflow evaluations, and design decisions, ensuring the system addresses the realities of modern operating rooms and the needs of surgical teams.
“Symphera’s multifunctional tool-tip design has the potential to revolutionize laparoscopic surgery. This unique concept could also be applied to therapeutic endoscopy and robotics in the future,” said Dr. Parker.
Symphera Awarded Highly Competitive EIC Accelerator Grant for Surgical Platform Development
The European Union grant supports Symphera’s work toward bringing its device to market.
Symphera has been awarded a highly competitive EIC Accelerator grant to accelerate development of its next-generation surgical platform. The funding supports the company’s technical roadmap and enables faster progress toward verification and regulatory submission.
The grant will be dedicated to engineering and validation activities, reinforcing Symphera’s strategic goal of delivering a more streamlined surgical workflow for minimally invasive procedures. It allows the company to move faster and invest deeper into the areas that will shape the platform’s impact.
Symphera becomes part of FDAs Safer Technologies Program (STeP)
The FDA’s STeP program recognizes technologies with strong potential to improve patient safety.
Symphera has been accepted into the FDA’s Safer Technologies Program (STeP), a pathway designed to support the development of medical technologies that may meaningfully improve safety during clinical procedures. The selection acknowledges Symphera’s potential to enhance consistency and workflow control through automated instrument switching.
Participation in STeP gives Symphera enhanced interaction with the FDA as the company advances engineering work, risk-management activities, and upcoming pre-clinical studies. The collaboration will help ensure the system aligns with rigorous safety expectations from the earliest stages of development.
Symphera Joins German Accelerator, gaining access to leading healthcare network
The program provides Symphera with strategic mentorship and direct entry points into the US market.
Symphera has been selected for the prestigious German Accelerator US Life Sciences program, joining a competitive group of high-growth companies preparing to enter the American healthcare ecosystem. Participation will support Symphera’s expansion strategy and strengthen its access to experienced mentors and clinical partners.
Through the program, Symphera will refine its go-to-market approach, gain insights into US regulatory pathways, and build relationships with clinical and commercial stakeholders as it advances its platform toward future international evaluation.